表紙
市場調査レポート

ユビキチンプロテアソーム:研究ツール・診断・創薬の世界市場

Ubiquitin Proteasome: Global Markets for Research Tools, Diagnostics and Drug Discovery

発行 BCC Research 商品コード 274470
出版日 ページ情報 英文 150 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
ユビキチンプロテアソーム:研究ツール・診断・創薬の世界市場 Ubiquitin Proteasome: Global Markets for Research Tools, Diagnostics and Drug Discovery
出版日: 2013年06月24日 ページ情報: 英文 150 Pages
概要

当レポートでは、世界のユビキチンプロテアソーム(UPS)研究分野における研究ツール、診断および創薬の状況について調査しており、世界市場の動向分析、市場における既存製品の議論、UPSにおける2大研究動向の特定(プロテアソーム阻害剤vs.薬剤標的としてのユビキチン化反応要素)、および創薬に影響を及ぼす動向などについてまとめ、概略下記の構成で取り上げております。

第1章 イントロダクション

第2章 サマリー

第3章 ユビキチンプロテアソーム研究の科学的背景・重要性

  • 概要

第4章 ユビキチンプロテアソームシステムと創薬

  • 創薬におけるプロテアソーム機構
  • 創薬標的としてのユビキチン化酵素
  • 創薬標的としての脱ユビキチン化酵素

第5章 診断ツールとしてのユビキチンプロテアソームシステム

  • 概要

第6章 ユビキチンプロテアソーム研究・創薬向け試薬・アッセイ開発

  • 概要

第7章 ユビキチンプロテアソーム開発における画期的な出来事および重要特許

  • ユビキチンプロテアソーム開発における主な画期的事件

第8章 市場サマリー

第9章 主要企業・プロファイル

  • CELGENE CORPORATION
  • ELAN PHARMACEUTICALS
  • GENENTECH (HOFFMANN-LA ROCHE AG)
  • F. HOFFMANN-LA ROCHE LTD.
  • JOHNSON & JOHNSON
  • MILLENNIUM PHARMACEUTICALS: THE TAKEDA ONCOLOGY COMPANY
  • ONYX PHARMACEUTICALS INC.
  • PROGENRA
  • PROTEOLOGICS LTD.
  • UBIQUIGENT LTD.

第10章 本レポートで言及した企業のリスト

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHM066B

This report provides:

  • An overview of the state of research tools, diagnostics, and drug discovery in the global ubiquitin proteasome (UPS) research field.
  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
  • Discussion of existing products in the market.
  • Identification of two major research trends in UPS: proteasome inhibitors versus ubiquitination reaction components as drug targets.
  • This study notes the trends that are going to affect further drug development in this area.

image1

REPORT SCOPE

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This BCC Research report, Ubiquitin Proteasome: Global Markets for Research Tools, Diagnostics and Drug Discovery, provides an overview of the current overall state of ubiquitin proteasome market, focusing specifically on research tools, assay development, drug candidates and potential diagnostic applications. It describes existing drug pipelines and scientific platforms on the market, and provides a detailed analysis of the competitive environments, including new potential trends and markets for novel therapies and product development. This study includes information about significant players, trends and obstacles and other information affecting this market and its different sectors.

REASONS FOR DOING THIS STUDY

Ubiquitin proteasome system (UPS) represents one of the most studied and challenging areas in basic and applicable science. Indeed, the scientists who discovered this cellular phenomenon were awarded the Nobel Prize in Chemistry in 2004. Since 2004, ubiquitin ligases and proteasome function have become one of the major targets for pharmaceutical and drug development companies.

However, despite the accumulation of basic knowledge about the mechanism of action of ubiquitination process and proteasome function, progress in drug screening and therapeutic development has been delayed. However, the proven success of the proteasome inhibitor Velcade (bortezomib) in addition to a recent breakthrough in the identification of new drug candidates in the UPS research field bring new excitement and hope for further successful drug development. Indeed, new second-generation proteasome inhibitor Kyprolis was recently approved by the FDA.

Moreover, the real commercial potential of this research area has not yet been fully acknowledged. Therefore, this study will provide knowledge of the current state of drug discovery in this field and new technologies in assay development and, more importantly, will describe potential novel commercial venues in diagnostics and drug development.

Overall, this report highlights the main segments in the ubiquitin proteasome market: reagents and technological platforms required for the research, drug discovery pipelines and potential applications of UPS in different areas of industry. It discusses its major players, current and future trends, and influences. Drivers and challenges in each segment of this industry are described in detail, including forecasts for the next five years.

SCOPE AND FORMAT

This report is essentially a business tool that can help market players evaluate properly new commercial opportunities in the ubiquitin proteasome space especially in the drug discovery, diagnostics and research tools submarkets. The geographic scope of this study is global. This market is generally complex and consists of a number of different segments, each of which is affected differently by scientific and technological developments. This report identifies the main positive and negative factors affecting each segment and forecasts market growth, future trends and product development in every major segment of this market.

METHODOLOGY AND INFORMATION SOURCES

Both primary and secondary research methodologies were used in preparing this study. Initially, a comprehensive and exhaustive search of the literature on drug discovery and already marketed products was conducted. These secondary sources included drug discovery and science-related journals, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports and other publications. A patent search and analysis were also conducted.

In a second phase, a series of semi-structured interviews was conducted with company representatives, bench scientists, marketing representatives and other personnel at biotechnology and pharmaceutical companies. Other sources included academics, technology and consulting companies. Subsequent analysis of the documents and interviews notes was iterative.

INTENDED AUDIENCE

This report is intended for business development professionals, entrepreneurs, and other investors who need to fully understand and properly evaluate each segment in the market for ubiquitin proteasome drug discovery, diagnostics and research tools applications. It provides insight into the market position of major companies and shows new opportunities otherwise overlooked or less known to the business community.

ANALYST CREDENTIALS

Dr. Marianna Tcherpakov has more than eight years of experience as a bench scientist specializing in biochemistry, cell biology and industrial assay development. She has contributed to a number of scientific publications and holds several patents. She has expertise as an assay development scientist and is familiar with different research field trends and likely future developments.

Table of Contents

Chapter- 1: INTRODUCTION - Complimentary

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • SCOPE AND FORMAT
  • METHODOLOGY AND INFORMATION SOURCES
  • INTENDED AUDIENCE
  • ANALYST CREDENTIALS
  • RELATED REPORTS
  • BCC ON-LINE SERVICES
  • DISCLAIMER

Chapter- 2: SUMMARY

  • Table Summary : GLOBAL MARKET FOR UBIQUITIN PROTEASOME RESEARCH AND DEVELOPMENT, THROUGH 2018
  • Figure Summary : GLOBAL MARKET FOR UBIQUITIN PROTEASOME RESEARCH AND DEVELOPMENT, 2010-2018

Chapter- 3: SCIENTIFIC BACKGROUND AND SIGNIFICANCE OF UBIQUITIN PROTEASOME RESEARCH

  • OVERVIEW

Chapter- 4: UBIQUITIN PROTEASOME SYSTEM AND DRUG DISCOVERY

  • PROTEASOME MACHINERY IN DRUG DISCOVERY
  • UBIQUITINATION ENZYMES AS A TARGET FOR DRUG DISCOVERY
  • DEUBIQUITINASES AS A TARGET FOR DRUG DISCOVERY

Chapter- 5: THE UBIQUITIN PROTEASOME SYSTEM AS A DIAGNOSTIC TOOL

  • OVERVIEW

Chapter- 6: REAGENTS AND ASSAY DEVELOPMENT FOR UPS RESEARCH AND DRUG DISCOVERY

  • OVERVIEW

Chapter- 7: MILESTONES IN UBIQUITIN-PROTEASOME MARKET DEVELOPMENT AND SIGNIFICANCE OF PATENTS9$491

  • MAIN MILESTONES IN UBIQUITIN-PROTEASOME MARKET DEVELOPMENT

Chapter- 8: MARKET SUMMARY4$218

  • Table 65 : WORLDWIDE MARKET FOR VELCADE AND KYPROLIS, THROUGH 2018
  • Figure 9 : WORLDWIDE MARKET FOR VELCADE AND KYPROLIS, 2010-2018
  • Table 66 : DIFFERENT TARGETS OF UPS IN CURRENT DRUG DEVELOPMENT COMPANIES
  • Table 67 : REAGENTS AND ASSAY DEVELOPMENT COMPANIES FOR UPS DRUG DISCOVERY

Chapter- 9: SELECT COMPANIES AND PROFILES

  • CELGENE CORPORATION
  • ELAN PHARMACEUTICALS
  • GENENTECH (HOFFMANN-LA ROCHE AG)
  • F. HOFFMANN-LA ROCHE LTD.
  • JOHNSON & JOHNSON
  • MILLENNIUM PHARMACEUTICALS: THE TAKEDA ONCOLOGY COMPANY
  • ONYX PHARMACEUTICALS INC.
  • PROGENRA
  • PROTEOLOGICS LTD.
  • UBIQUIGENT LTD.

Chapter- 10: LIST OF COMPANIES MENTIONED IN REPORT

  • ACENTA THERAPEUTICS
  • AEGERA THERAPEUTICS INC. (PART OF PHARMASCIENCE INC.)
  • AMGEN INC.
  • ASTELLAS PHARMA U.S. INC.
  • BIOGENOVA CORP.
  • BOSTON BIOCHEM INC. (R&D SYSTEMS)
  • BRISTOL-MYERS SQUIBB
  • CELGENE CORPORATION
  • CELLCENTRIC LTD.
  • CELLXPLORE
  • CISBIO
  • CLEAVE BIOSCIENCES
  • DUALSYSTEMS BIOTECH AG
  • ELAN PHARMACEUTICAL
  • ENZO LIFE SCIENCES INC.
  • GENENTECH INC. (ROCHE GROUP)
  • GSK (GLAXOSMITHKLINE PLC)
  • HYBRIGENICS
  • JOHNSON AND JOHNSON
  • F. HOFFMANN-LA ROCHE AG
  • LIFE SENSORS INC.
  • LIFE TECHNOLOGIES CORP. (THERMO FISHER SCIENTIFIC)
  • MESO SCALE DISCOVERY
  • MERCK CORPORATE HEADQUARTERS
  • MILLENIUM PHARMACEUTICAL (THE TAKEDA ONCOLOGY COMPANY)
  • MISSION THERAPEUTICS LTD.
  • NEXUSPHARMA INC.
  • NOVARTIS INTERNATIONAL AG
  • ONYX PHARMACEUTICALS INC.
  • PRIAXON AG
  • PROGENRA INC.
  • PROTEOLOGICS LTD.
  • PROTEOSTASIS THERAPEUTICS
  • RIGEL PHARMACEUTICALS INC.
  • SCIL PROTEINS GMBH
  • SIGMA-ALDRICH
  • THERMO FISHER SCIENTIFIC INC.
  • TEVA PHARMACEUTICALS
  • TETRALOGICS PHARMACEUTICALS
  • UBIQ BIO BV
  • UBIQUIGENT LTD.

List of Tables

  • Summary Table : GLOBAL MARKET FOR UBIQUITIN PROTEASOME RESEARCH AND DEVELOPMENT, THROUGH 2018
  • Table 1 : ENZYMATIC COMPONENTS OF UBIQTUINATION/ DEUBIQUITINATION REACTION
  • Table 2 : UBIQUITIN LIKE MODIFIERS (UBLS), THEIR FUNCTION AND ASSOCIATED SUBSTRATES
  • Table 3 : U.S. STATISTICS FOR HEMATOLOGICAL MALIGNANCIES, 2011
  • Table 4 : MARKET SIZE FOR MULTIPLE MYELOMA DRUG MARKET, THROUGH 2018
  • Table 5 : EXAMPLE OF COST OF SIDE EFFECT FOR CHEMOTHERAPY TREATMENT IN 2006 IN U.S. PER PATIENT
  • Table 6 : U.S. AND WORLDWIDE NET SALES FOR VELCADE, THROUGH 2018
  • Table 7 : NET SALES FOR REVLIMID AND THALOMID, THROUGH 2018
  • Table 8 : NET SALES FOR KYPROLIS, THROUGH 2018
  • Table 9 : MARKET SHARE BETWEEN CELGENE AND MILLENIUM PHARMACEUTICALS/TAKEDA AND OTHER DRUG COMPANIES IN 2009, 2012 AGAINST POSSIBLE MARKET SHARE IN 2016 AND AFTER
  • Table 10 : CURRENT R&D ACTIVITY IN UBIQUITIN/PROTEASOME RESEARCH IN MILLENIUM PHARMACEUTICALS
  • Table 11 : COMPANIES WITH CURRENT R&D IN PROTEASOME INHIBITION AS A DRUG TARGET
  • Table 12 : GENERAL MARKET WORTH FOR AUTOIMMUNE DISORDERS: LUPUS, RHEUMATOID ARTHRITIS AND IBD IN 2010
  • Table 13 : ACTIVITY OF PROTEASOME INHIBITORS IN ANIMAL MODELS FOR AUTOIMMUNE AND INFLAMMATORY DISEASES
  • Table 14 : MARKET SIZE FOR HAIR LOSS TREATMENT IN THE U.S.
  • Table 15 : GLOBAL MARKET SIZE FOR ANTI-AGING PRODUCTS
  • Table 16 : STATISTICS FOR TUBERCULOSIS INFECTION WORLDWIDE AND IN THE U.S., 2009
  • Table 17 : POTENTIAL MARKET WORTH FOR TUBERCULOSIS DRUG TREATMENT, 2009-2017
  • Table 18 : MARKET SIZE FOR DRY EYE TREATMENT, 2009 AND 2013
  • Table 19 : CURRENT DRUG DISCOVERY FOR E1 INHIBITORS
  • Table 20 : E2S AS A DRUG DISCOVERY TARGET AND ITS MARKET POTENTIAL
  • Table 21 : MARKET POTENTIALS FOR SCA TREATMENT
  • Table 22 : COMPANIES THAT WORK ON E3 LIGASES AS A DRUG TARGET
  • Table 23 : DRUG DISCOVERY APPROACH FOR P53 STUDIES
  • Table 24 : COMPANIES WITH R&D IN P53 GENE THERAPY
  • Table 25 : U.S. STATISTICS AND GLOBAL MARKET SIZE FOR HEAD AND NECK AND OVARIAN CANCERS, 2009
  • Table 26 : STRATEGIES FOR HDM2-P53 DRUG DISCOVERY
  • Table 27 : LIST OF COMPANIES AND DRUG CANDIDATES IN HDM2/P53 DRUG DISCOVERY
  • Table 28 : CURRENT COMPANIES WITH R&D PROGRAM IN IAP DRUG DISCOVERY
  • Table 29 : POTENTIAL MARKETS SIZE FOR IAPS DRUG DISCOVERY
  • Table 30 : LIST OF E3 UBIQUITIN LIGASES IN DRUG DISCOVERY
  • Table 31 : STATISTICS FOR RA IN THE U.S. AND GLOBAL ESTIMATE FOR RA MARKET, 2009 AND 2030
  • Table 32 : STATISTICS FOR OSTEOPOROSIS IN THE U.S. AND GLOBAL ESTIMATE FOR OSTEOPOROSIS MARKET
  • Table 33 : POTENTIAL MARKETS FOR CURRENT PROJECTS IN E3 LIGASE DRUG DISCOVERY
  • Table 34 : ADDITIONAL E3 LIGASES AS POTENTIAL DRUG DISCOVERY TARGETS
  • Table 35 : BREAST CANCER STATISTICS IN WOMEN IN THE U.S., 2009
  • Table 36 : MARKET FOR BREAST CANCER THERAPEUTICS, THROUGH 2016
  • Table 37 : DEUBIQUITINASES AND THEIR ROLE IN CLINICAL CONDITIONS
  • Table 38 : EXAMPLES OF POTENTIAL MARKETS FOR DUBS DRUG DISCOVERY
  • Table 39 : EXAMPLES OF DUBS INHIBITORS AND THEIR TARGETS
  • Table 40 : COMPANIES WORKING ON DUBS AS DRUG TARGET
  • Table 41 : STATISTICS AND COST OF MEDICAL CARE IN LUNG AND COLON CANCER IN THE U.S., 2009
  • Table 42 : ENZYMATIC MACHINERY OF SUMOYLATION
  • Table 43 : GLOBAL BIOMARKERS MARKET, THROUGH 2015
  • Table 44 : WORLDWIDE MARKET FOR BIOMARKERS ACCORDING TO DIFFERENT RESEARCH AREAS, 2013
  • Table 45 : ANALYSIS OF SCIENTIFIC PUBLICATION ON UBIQUITIN PROTEASOME SYSTEM
  • Table 46 : MARKET FOR BREAST CANCER DIAGNOSTICS, THROUGH 2016
  • Table 47 : WORLDWIDE STATISTICS AND GLOBAL MARKET SIZE FOR MULTIPLE SCLEROSIS AND RHEUMATOID ARTHRITIS
  • Table 48 : MARKET FOR IMMUNE DISORDERS DIAGNOSTICS
  • Table 49 : MARKET SIZE FOR REPRESENTATIVE NEURODEGENARATION DISORDERS AND STATISTICS OF INCIDENCE IN THE U.S.
  • Table 50 : NET SALES OF REQUIP, 2010-2012
  • Table 51 : NET SALES OF NAMENDA IN THE LAST THREE YEARS, 2010-2012
  • Table 52 : STATISTICS FOR HUNTIGNTON CONDITION IN THE U.S. AND GLOBAL MARKET SIZE FOR HUNTINGTON'S DISEASE
  • Table 53 : STATISTICS AND COST OF IBD IN THE U.S.
  • Table 54 : STATISTICS AND COST OF HCC IN USA
  • Table 55 : COMPANIES INVOLVED IN MARKETING OF RESEARCH TOOLS FOR UPS, NUMBER OF PRODUCTS AND REVENUE OF THE COMPANY, 2010
  • Table 56 : EXAMPLE OF COMMON UPS REAGENTS PRICES IN MAJOR SUPPLIERS OF UPS REAGENT TOOL COMPANIES
  • Table 57 : PROVIDERS OF SCREENING ASSAY TOOLS
  • Table 58 : COMPANIES SELLING UBIQUITIN AND UBIQUITIN-LIKE MODIFIERS AS REAGENT TOOL FOR OTHER DRUG DISCOVERIES APPLICATIONS
  • Table 59 : SCIENTIFIC AND TECHNOLOGICAL BREAKTHROUGHS IN UPS, 1977-2012
  • Table 60 : MARKET VALUE OF COTTON AND CORN IN THE U.S.
  • Table 61 : PATENT APPLICATIONS FILED BY PHARMACEUTICAL COMPANIES DURING 2012
  • Table 62 : PATENT APPLICATIONS FILED BY PHARMACEUTICAL COMPANIES DURING 2006
  • Table 63 : NUMBER OF PATENT APPLICATIONS IN UBIQUITIN/ PROTEASOME RESEARCH FILED BY LEADING PHARMACEUTICAL COMPANIES, 1995-2013
  • Table 64 : PERCENTAGES OF PATENT APPLICATIONS IN UPS RESEARCH FILED IN THE U.S., EUROPE AND JAPAN
  • Table 65 : WORLDWIDE MARKET FOR VELCADE AND KYPROLIS, THROUGH 2018
  • Table 66 : DIFFERENT TARGETS OF UPS IN CURRENT DRUG DEVELOPMENT COMPANIES
  • Table 67 : REAGENTS AND ASSAY DEVELOPMENT COMPANIES FOR UPS DRUG DISCOVERY

List of Figures

  • Summary Figure : GLOBAL MARKET FOR UBIQUITIN PROTEASOME RESEARCH AND DEVELOPMENT, 2010-2018
  • Figure 1 : SCHEMATIC REPRESENTATION OF ENZYMATIC STEPS IN UBIQUITINATION REACTION
  • Figure 2 : HIERARCHICAL STRUCTURE OF UBIQUITINE PROTEASOME SYSTEM
  • Figure 3 : CHEMICAL STRUCTURE OF BORTEZOMIB
  • Figure 4 : U.S. AND WORLDWIDE NET SALES FOR VELCADE, 2009-2018
  • Figure 5 : NET SALES FOR REVLIMID AND THALOMID, 2009-2018
  • Figure 6 : NET SALES FOR KYPROLIS, 2011-2018
  • Figure 7 : EXAMPLE OF COMMON UPS REAGENTS PRICES IN MAJOR SUPPLIERS OF UPS REAGENT TOOL COMPANIES
  • Figure 8 : NUMBER OF PATENT APPLICATIONS IN UBIQUITIN/PROTEASOME RESEARCH FILED BY LEADING PHARMACEUTICAL COMPANIES, 1995-2013
  • Figure 9 : WORLDWIDE MARKET FOR VELCADE AND KYPROLIS, 2010-2018
Back to Top